1. Home
  2. OMER vs VABK Comparison

OMER vs VABK Comparison

Compare OMER & VABK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMER
  • VABK
  • Stock Information
  • Founded
  • OMER 1994
  • VABK 1998
  • Country
  • OMER United States
  • VABK United States
  • Employees
  • OMER N/A
  • VABK N/A
  • Industry
  • OMER Biotechnology: Pharmaceutical Preparations
  • VABK Major Banks
  • Sector
  • OMER Health Care
  • VABK Finance
  • Exchange
  • OMER Nasdaq
  • VABK Nasdaq
  • Market Cap
  • OMER 188.1M
  • VABK 199.2M
  • IPO Year
  • OMER 2009
  • VABK N/A
  • Fundamental
  • Price
  • OMER $3.61
  • VABK $37.31
  • Analyst Decision
  • OMER Strong Buy
  • VABK
  • Analyst Count
  • OMER 5
  • VABK 0
  • Target Price
  • OMER $18.00
  • VABK N/A
  • AVG Volume (30 Days)
  • OMER 951.8K
  • VABK 5.3K
  • Earning Date
  • OMER 08-06-2025
  • VABK 07-22-2025
  • Dividend Yield
  • OMER N/A
  • VABK 3.78%
  • EPS Growth
  • OMER N/A
  • VABK 3.77
  • EPS
  • OMER N/A
  • VABK 3.30
  • Revenue
  • OMER N/A
  • VABK $54,953,000.00
  • Revenue This Year
  • OMER N/A
  • VABK N/A
  • Revenue Next Year
  • OMER $3,446.91
  • VABK N/A
  • P/E Ratio
  • OMER N/A
  • VABK $11.53
  • Revenue Growth
  • OMER N/A
  • VABK 1.60
  • 52 Week Low
  • OMER $2.95
  • VABK $33.53
  • 52 Week High
  • OMER $13.60
  • VABK $44.00
  • Technical
  • Relative Strength Index (RSI)
  • OMER 52.22
  • VABK 49.11
  • Support Level
  • OMER $3.00
  • VABK $37.50
  • Resistance Level
  • OMER $3.25
  • VABK $38.70
  • Average True Range (ATR)
  • OMER 0.26
  • VABK 0.72
  • MACD
  • OMER 0.12
  • VABK 0.03
  • Stochastic Oscillator
  • OMER 61.97
  • VABK 33.81

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

About VABK Virginia National Bankshares Corporation

Virginia National Bankshares Corp is a bank holding company which is engaged in the commercial and retail banking business. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts and other depository services. Its segments include the Bank, VNB Trust and Estate Services, Sturman Wealth Advisors, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits and offering related services to individuals, businesses, and charitable organizations.

Share on Social Networks: